0001829959false3/31/202312/3100018299592023-03-31iso4217:USD00018299592022-12-3100018299592023-01-012023-03-3100018299592022-01-012022-03-31iso4217:USDxbrli:sharesxbrli:shares0001829959ifrs-full:OrdinarySharesMember2021-12-310001829959ifrs-full:AdditionalPaidinCapitalMember2021-12-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2021-12-310001829959ifrs-full:RetainedEarningsMember2021-12-3100018299592021-12-310001829959ifrs-full:OrdinarySharesMember2022-01-012022-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2022-01-012022-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001829959ifrs-full:RetainedEarningsMember2022-01-012022-03-310001829959ifrs-full:OrdinarySharesMember2022-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2022-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-03-310001829959ifrs-full:RetainedEarningsMember2022-03-3100018299592022-03-310001829959ifrs-full:OrdinarySharesMember2022-12-310001829959ifrs-full:AdditionalPaidinCapitalMember2022-12-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2022-12-310001829959ifrs-full:RetainedEarningsMember2022-12-310001829959ifrs-full:OrdinarySharesMember2023-01-012023-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2023-01-012023-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001829959ifrs-full:RetainedEarningsMember2023-01-012023-03-310001829959ifrs-full:OrdinarySharesMember2023-03-310001829959ifrs-full:AdditionalPaidinCapitalMember2023-03-310001829959ifrs-full:AccumulatedOtherComprehensiveIncomeMember2023-03-310001829959ifrs-full:RetainedEarningsMember2023-03-310001829959docebo:DoceboSpAMember2023-01-012023-03-31xbrli:pure0001829959docebo:DoceboSpAMember2022-01-012022-12-310001829959docebo:DoceboNAIncMember2023-01-012023-03-310001829959docebo:DoceboNAIncMember2022-01-012022-12-310001829959docebo:DoceboEMEAFZLLCMember2023-01-012023-03-310001829959docebo:DoceboEMEAFZLLCMember2022-01-012022-12-310001829959docebo:DoceboUKMember2023-01-012023-03-310001829959docebo:DoceboUKMember2022-01-012022-12-310001829959docebo:DoceboFranceMember2023-01-012023-03-310001829959docebo:DoceboFranceMember2022-01-012022-12-310001829959docebo:DoceboGermanyMember2023-01-012023-03-310001829959docebo:DoceboGermanyMember2022-01-012022-12-310001829959docebo:DoceboAustraliaPtyLtdMember2023-01-012023-03-310001829959docebo:DoceboAustraliaPtyLtdMember2022-01-012022-12-310001829959docebo:DoceboIrelandLimitedMember2023-01-012023-03-310001829959docebo:DoceboIrelandLimitedMember2022-01-012022-12-310001829959ifrs-full:TradeReceivablesMember2023-03-310001829959ifrs-full:TradeReceivablesMember2022-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherPropertyPlantAndEquipmentMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMember2023-03-310001829959ifrs-full:LandAndBuildingsMember2022-12-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMember2022-12-310001829959ifrs-full:LandAndBuildingsMember2023-03-310001829959ifrs-full:OtherPropertyPlantAndEquipmentMember2023-03-310001829959docebo:FurnituresAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959docebo:FurnituresAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959docebo:FurnituresAndOfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:LeaseholdImprovementsMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:LandAndBuildingsMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberdocebo:FurnituresAndOfficeEquipmentMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LeaseholdImprovementsMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:LandAndBuildingsMember2023-03-310001829959docebo:FurnituresAndOfficeEquipmentMember2022-12-310001829959ifrs-full:LeaseholdImprovementsMember2022-12-310001829959ifrs-full:LandAndBuildingsMember2022-12-310001829959docebo:FurnituresAndOfficeEquipmentMember2023-03-310001829959ifrs-full:LeaseholdImprovementsMember2023-03-310001829959ifrs-full:LandAndBuildingsMember2023-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:TechnologybasedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:BrandNamesMemberifrs-full:GrossCarryingAmountMember2022-12-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:TechnologybasedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:BrandNamesMemberifrs-full:GrossCarryingAmountMember2023-01-012023-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:TechnologybasedIntangibleAssetsMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:BrandNamesMemberifrs-full:GrossCarryingAmountMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2022-12-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2023-01-012023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:CustomerrelatedIntangibleAssetsMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:TechnologybasedIntangibleAssetsMember2023-03-310001829959ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:BrandNamesMember2023-03-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMember2022-12-310001829959ifrs-full:TechnologybasedIntangibleAssetsMember2022-12-310001829959ifrs-full:BrandNamesMember2022-12-310001829959ifrs-full:CustomerrelatedIntangibleAssetsMember2023-03-310001829959ifrs-full:TechnologybasedIntangibleAssetsMember2023-03-310001829959ifrs-full:BrandNamesMember2023-03-310001829959ifrs-full:GoodwillMember2022-12-310001829959ifrs-full:GoodwillMember2023-01-012023-03-310001829959ifrs-full:GoodwillMember2023-03-310001829959docebo:EmployeeStockOptionMember2023-01-012023-03-310001829959docebo:EmployeeStockOptionMember2022-01-012022-03-310001829959docebo:DeferredShareUnitsDSUMember2023-01-012023-03-310001829959docebo:DeferredShareUnitsDSUMember2022-01-012022-03-310001829959docebo:RestrictedStockUnitsMember2023-01-012023-03-310001829959docebo:RestrictedStockUnitsMember2022-01-012022-03-310001829959docebo:EmployeeSharePurchasePlanMember2023-01-012023-03-310001829959docebo:EmployeeSharePurchasePlanMember2022-01-012022-03-310001829959docebo:PerformanceShareUnitsMember2023-03-310001829959docebo:PerformanceShareUnitsMember2022-03-310001829959ifrs-full:CostOfSalesMember2023-01-012023-03-310001829959ifrs-full:CostOfSalesMember2022-01-012022-03-310001829959docebo:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001829959docebo:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001829959docebo:SalesAndMarketingExpenseMember2023-01-012023-03-310001829959docebo:SalesAndMarketingExpenseMember2022-01-012022-03-310001829959docebo:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001829959docebo:ResearchAndDevelopmentExpenseMember2022-01-012022-03-31iso4217:CADxbrli:shares0001829959docebo:ExercisePriceRangeOneMemberifrs-full:BottomOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:TopOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeOneMember2023-03-310001829959docebo:ExercisePriceRangeOneMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:BottomOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:TopOfRangeMember2023-03-310001829959docebo:ExercisePriceRangeTwoMember2023-03-310001829959docebo:ExercisePriceRangeTwoMember2023-01-012023-03-310001829959ifrs-full:BottomOfRangeMemberdocebo:ExercisePriceRangeThreeMember2023-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeThreeMember2023-03-310001829959docebo:ExercisePriceRangeThreeMember2023-03-310001829959docebo:ExercisePriceRangeThreeMember2023-01-012023-03-310001829959ifrs-full:BottomOfRangeMemberdocebo:ExercisePriceRangeFiveMember2023-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeFiveMember2023-03-310001829959docebo:ExercisePriceRangeFiveMember2023-03-310001829959docebo:ExercisePriceRangeFiveMember2023-01-012023-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:BottomOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeOneMemberifrs-full:TopOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeOneMember2022-03-310001829959docebo:ExercisePriceRangeOneMember2022-01-012022-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:BottomOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeTwoMemberifrs-full:TopOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeTwoMember2022-03-310001829959docebo:ExercisePriceRangeTwoMember2022-01-012022-03-310001829959ifrs-full:BottomOfRangeMemberdocebo:ExercisePriceRangeThreeMember2022-03-310001829959ifrs-full:TopOfRangeMemberdocebo:ExercisePriceRangeThreeMember2022-03-310001829959docebo:ExercisePriceRangeThreeMember2022-03-310001829959docebo:ExercisePriceRangeThreeMember2022-01-012022-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:BottomOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeFourMemberifrs-full:TopOfRangeMember2022-03-310001829959docebo:ExercisePriceRangeFourMember2022-03-310001829959docebo:ExercisePriceRangeFourMember2022-01-012022-03-310001829959docebo:DeferredShareUnitsDSUMember2022-12-310001829959docebo:DeferredShareUnitsDSUMember2023-03-310001829959docebo:RestrictedStockUnitsMember2022-12-310001829959docebo:RestrictedStockUnitsMemberifrs-full:BottomOfRangeMember2023-01-012023-03-310001829959docebo:RestrictedStockUnitsMemberifrs-full:TopOfRangeMember2023-01-012023-03-310001829959docebo:RestrictedStockUnitsMember2023-03-310001829959docebo:EmployeeStockOptionMember2022-01-012022-03-310001829959docebo:DeferredShareUnitsDSUMember2022-01-012022-03-310001829959docebo:RestrictedStockUnitsMember2022-01-012022-03-31docebo:revenue_source0001829959docebo:SubscriptionRevenueMember2023-01-012023-03-310001829959docebo:SubscriptionRevenueMember2022-01-012022-03-310001829959docebo:ProfessionalServicesRevenueMember2023-01-012023-03-310001829959docebo:ProfessionalServicesRevenueMember2022-01-012022-03-310001829959srt:NorthAmericaMember2023-01-012023-03-310001829959srt:NorthAmericaMember2022-01-012022-03-310001829959docebo:RestOfWorldMember2023-01-012023-03-310001829959docebo:RestOfWorldMember2022-01-012022-03-310001829959docebo:CirclesCollectiveIncMemberifrs-full:MajorBusinessCombinationMember2023-04-300001829959docebo:FirstYearAnniversaryMember2023-04-300001829959docebo:SecondYearAnniversaryMember2023-04-300001829959docebo:CirclesCollectiveIncMemberifrs-full:MajorBusinessCombinationMember2023-04-012023-04-3000018299592023-04-012023-04-30
| | |
|
DOCEBO INC. |
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION |
|
(expressed in thousands of United States dollars) |
| | | | | | | | | | | |
| | | |
| March 31, | | December 31, |
| 2023 | | 2022 |
| $ | | $ |
Assets | | | |
Current assets: | | | |
Cash and cash equivalents | 215,831 | | | 216,293 | |
Trade and other receivables (Note 4) | 45,481 | | | 37,527 | |
Income taxes receivable | 190 | | | 435 | |
Prepaids and deposits | 8,654 | | | 6,378 | |
Net investment in finance lease | 81 | | | 174 | |
Contract costs, net | 4,732 | | | 2,778 | |
| 274,969 | | | 263,585 | |
Non-current assets: | | | |
Contract costs, net | 8,260 | | | 7,931 | |
Net investment in finance lease | 100 | | | 241 | |
Deferred tax asset | 130 | | | 118 | |
Right-of-use assets, net (Note 5) | 2,082 | | | 2,038 | |
Property and equipment, net (Note 6) | 2,469 | | | 2,624 | |
Intangible assets, net (Note 7) | 1,085 | | | 1,150 | |
Goodwill (Note 8) | 6,059 | | | 5,982 | |
| 295,154 | | | 283,669 | |
| | | |
Liabilities | | | |
Current liabilities: | | | |
Trade and other payables | 29,430 | | | 26,025 | |
Income taxes payable | 151 | | | 101 | |
Deferred revenue | 60,593 | | | 55,779 | |
Contingent consideration | 1,083 | | | 1,083 | |
Lease obligations (Note 5) | 1,626 | | | 1,374 | |
| | | |
| 92,883 | | | 84,362 | |
Non-current liabilities: | | | |
Contingent consideration | 1,193 | | | 1,177 | |
Deferred revenue | 391 | | | 528 | |
Lease obligations (Note 5) | 1,431 | | | 1,692 | |
Employee benefit obligations | 2,652 | | | 2,423 | |
Deferred tax liability | 1,358 | | | 1,276 | |
| | | |
| 99,908 | | | 91,458 | |
| | | |
Shareholders’ equity | | | |
Share capital (Note 10) | 268,889 | | | 268,194 | |
Contributed surplus | 9,394 | | | 8,458 | |
Accumulated other comprehensive loss | (9,412) | | | (9,571) | |
Deficit | (73,625) | | | (74,870) | |
Total equity | 195,246 | | | 192,211 | |
| 295,154 | | | 283,669 | |
| | | |
| | | |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
1
| | |
DOCEBO INC. |
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) |
|
(expressed in thousands of United States dollars, except per share amounts) |
| | | | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Revenue (Note 13) | | | | | 41,459 | | | 32,055 | |
Cost of revenue (Note 14 and 15) | | | | | 8,054 | | | 6,552 | |
Gross profit | | | | | 33,405 | | | 25,503 | |
| | | | | | | |
Operating expenses | | | | | | | |
General and administrative (Note 15) | | | | | 7,556 | | | 7,375 | |
Sales and marketing (Note 15) | | | | | 16,772 | | | 13,747 | |
Research and development (Note 15) | | | | | 7,377 | | | 6,186 | |
Share-based compensation (Note 11) | | | | | 1,267 | | | 1,094 | |
Foreign exchange loss | | | | | 102 | | | 3,391 | |
Depreciation and amortization (Note 5, 6 and 7) | | | | | 707 | | | 580 | |
| | | | | 33,781 | | | 32,373 | |
Operating loss | | | | | (376) | | | (6,870) | |
| | | | | | | |
Finance income, net (Note 9) | | | | | (2,167) | | | (19) | |
Other expense (income), net | | | | | 183 | | | (21) | |
Income (loss) before income taxes | | | | | 1,608 | | | (6,830) | |
| | | | | | | |
Income tax expense | | | | | 363 | | | 129 | |
| | | | | | | |
Net income (loss) for the periods | | | | | 1,245 | | | (6,959) | |
| | | | | | | |
Other comprehensive income | | | | | | | |
Item that may be reclassified subsequently to income: | | | | | | | |
Exchange gain on translation of foreign operations | | | | | (159) | | | (3,212) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Comprehensive income (loss) | | | | | 1,404 | | | (3,747) | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Income (loss) per share - basic | | | | | 0.04 | | (0.21) |
Income (loss) per share - diluted | | | | | 0.04 | | (0.21) |
| | | | | | | |
Weighted average number of common shares outstanding - basic (Note 12) | | | | | 33,153,231 | | | 33,017,421 | |
Weighted average number of common shares outstanding - diluted (Note 12) | | | | | 34,159,651 | | | 33,017,421 | |
| | | | | | | |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
2
| | |
DOCEBO INC. |
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY |
|
(expressed in thousands of United States dollars, except number of shares) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Share capital | | Contributed surplus | | Accumulated other comprehensive income (loss) | | Deficit | | Total |
| # | | $ | | $ | | $ | | $ | | $ |
| | | | | | | | | | | |
Balance, December 31, 2021 | 32,857,422 | | | 266,119 | | | 4,312 | | | 2,113 | | | (81,888) | | | 190,656 | |
Exercise of stock options (Note 10 and 11) | 1,897 | | | 34 | | | (14) | | | — | | | — | | | 20 | |
Share-based compensation (Note 11) | — | | | — | | | 1,094 | | | — | | | — | | | 1,094 | |
| | | | | | | | | | | |
| | | | | | | | | | | |
Share issuance under employee share purchase plan (Note 10 and 11) | 6,377 | | | 361 | | | (57) | | | — | | | — | | | 304 | |
Comprehensive income (loss) | — | | | — | | | — | | | 3,212 | | | (6,959) | | | (3,747) | |
Balance, March 31, 2022 | 32,865,696 | | | 266,514 | | | 5,335 | | | 5,325 | | | (88,847) | | | 188,327 | |
| | | | | | | | | | | |
Balance, December 31, 2022 | 32,913,955 | | | 268,194 | | | 8,458 | | | (9,571) | | | (74,870) | | | 192,211 | |
Exercise of stock options (Note 10 and 11) | 8,735 | | | 149 | | | (49) | | | — | | | — | | | 100 | |
Share-based compensation (Note 11) | — | | | — | | | 1,267 | | | — | | | — | | | 1,267 | |
Share issuance under employee share purchase plan (Note 10 and 11) | 8,785 | | | 322 | | | (58) | | | — | | | — | | | 264 | |
| | | | | | | | | | | |
Release of restricted share units (Note 10 and 11) | 5,249 | | | 224 | | | (224) | | | — | | | — | | | — | |
| | | | | | | | | | | |
| | | | | | | | | | | |
Comprehensive income | — | | | — | | | — | | | 159 | | | 1,245 | | | 1,404 | |
Balance, March 31, 2023 | 32,936,724 | | | 268,889 | | | 9,394 | | | (9,412) | | | (73,625) | | | 195,246 | |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
3
| | |
DOCEBO INC. |
UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS |
|
(expressed in thousands of United States dollars) |
| | | | | | | | | | | |
| Three months ended March 31, |
| 2023 | | 2022 |
| $ | | $ |
Cash flows (used in) from operating activities | | | |
Net income (loss) | 1,245 | | | (6,959) | |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | | | |
Depreciation and amortization | 707 | | | 580 | |
Share-based compensation | 1,267 | | | 1,094 | |
Loss on disposal of asset | 197 | | | — | |
Unrealized foreign exchange loss | 126 | | | 3,194 | |
Income tax expense | 363 | | | 129 | |
Finance income, net | (2,167) | | | (19) | |
Changes in non-cash working capital items: | | | |
Trade and other receivables | (7,265) | | | (4,087) | |
| | | |
Prepaids and deposits | (2,217) | | | (968) | |
Contract costs | (2,233) | | | (3,015) | |
Trade and other payables | 3,178 | | | 1,220 | |
| | | |
Employee benefit obligations | 184 | | | 110 | |
Deferred revenue | 4,434 | | | 6,749 | |
| | | |
Cash used in operating activities | (2,181) | | | (1,972) | |
| | | |
Cash flows used in investing activities | | | |
Purchase of property and equipment | (107) | | | (303) | |
| | | |
Acquisition of business, net of cash acquired | — | | | (1,071) | |
Cash used in investing activities | (107) | | | (1,374) | |
| | | |
Cash flows (used in) from financing activities | | | |
Payments received on net investment in finance lease | 44 | | | 21 | |
Repayment of lease obligations | (451) | | | (345) | |
Interest received | 1,738 | | | 103 | |
Proceeds from exercise of stock options | 100 | | | 20 | |
| | | |
Proceeds from share issuance under employee share purchase plan | 264 | | | 304 | |
| | | |
| | | |
| | | |
| | | |
Cash from financing activities | 1,695 | | | 103 | |
| | | |
Net change in cash and cash equivalents during the period | (593) | | | (3,243) | |
Effect of foreign exchange on cash and cash equivalents | 131 | | | (98) | |
Cash and cash equivalents, beginning of the period | 216,293 | | | 215,323 | |
Cash and cash equivalents, end of the period | 215,831 | | | 211,982 | |
The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.
4
| | |
DOCEBO INC. |
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS |
March 31, 2023 |
(expressed in thousands of US dollars, except share amounts) |
Docebo Inc. (the “Company” or “Docebo”) is a provider of cloud-based learning management systems. The Company was incorporated on April 21, 2016 under the laws of the Province of Ontario. The Company’s head office is located at Suite 701, 366 Adelaide Street West, Toronto, Canada, M5V 1R9.
The Company’s shares are listed on both the Toronto Stock Exchange (“TSX”), as of October 8, 2019, and the Nasdaq Global Select Market (“Nasdaq”), as of December 3, 2020, under the stock symbol “DCBO”.
The Company has the following subsidiaries:
| | | | | | | | | | | | | | | | | |
Entity name | Country | | Ownership percentage March 31, 2023 | | Ownership percentage December 31, 2022 |
| | | % | | % |
Docebo S.p.A | Italy | | 100 | | 100 |
Docebo NA, Inc. | United States | | 100 | | 100 |
Docebo EMEA FZ-LLC | Dubai | | 100 | | 100 |
Docebo UK Limited | England | | 100 | | 100 |
Docebo France Société par Actions Simplifiée (“Docebo France”) | France | | 100 | | 100 |
Docebo DACH GmbH (“Docebo Germany”) | Germany | | 100 | | 100 |
Docebo Australia Pty Ltd. ("Docebo Australia") | Australia | | 100 | | 100 |
Docebo Ireland Limited | Ireland | | 100 | | 100 |
Statement of compliance
The unaudited condensed consolidated interim financial statements (“financial statements”) have been prepared by management using the same accounting policies and methods as those used in the Company’s consolidated financial statements for the year ended December 31, 2022. These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting. Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) have been omitted or condensed. These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2022.
These financial statements were approved and authorized for issuance by the Board of Directors of the Company on May 10, 2023.
Use of estimates, assumptions and judgments
The preparation of these financial statements in conformity with IFRS requires management to make estimates, assumptions and judgments that affect the application of accounting policies and the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results may differ from those estimates.
Estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
In preparing these financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of uncertainty are the same as those applied and described in the Company’s annual audited consolidated financial statements for the year ended December 31, 2022.
| | | | | |
3 | Summary of significant accounting policies |
The significant accounting policies applied in these financial statements are the same as those applied and described in the Company’s annual audited consolidated financial statements as at and for the year ended December 31, 2022.
| | | | | |
4 | Trade and other receivables |
The Company’s trade and other receivables as at March 31, 2023 and December 31, 2022 include the following:
| | | | | | | | | | | |
| 2023 | | 2022 |
| $ | | $ |
Trade receivables | 38,187 | | | 29,128 | |
Accrued revenues | 3,898 | | | 3,288 | |
Tax credits receivable | 2,854 | | | 3,054 | |
Interest receivable | 498 | | | 1,662 | |
Other receivables | 44 | | | 395 | |
| 45,481 | | | 37,527 | |
Included in trade receivables is a loss allowance of $859 as at March 31, 2023 and $719 as at December 31, 2022.
The Company’s right-of-use assets by class of assets are as follows:
| | | | | | | | | | | | | | | | | |
| Premises | | Others | | Total |
| $ | | $ | | $ |
Costs | | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Balance – December 31, 2022 | 4,717 | | 382 | | 5,099 |
Additions | 357 | | — | | 357 |
| | | | | |
Effects of foreign exchange | 55 | | 7 | | 62 |
Balance – March 31, 2023 | 5,129 | | 389 | | 5,518 |
| | | | | |
Accumulated amortization | | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
Balance – December 31, 2022 | 2,796 | | 265 | | 3,061 |
Amortization | 323 | | 13 | | 336 |
| | | | | |
Effects of foreign exchange | 30 | | 9 | | 39 |
Balance – March 31, 2023 | 3,149 | | 287 | | 3,436 |
| | | | | |
Carrying value | | | | | |
Net balance – December 31, 2022 | 1,921 | | 117 | | 2,038 |
Net balance – March 31, 2023 | 1,980 | | 102 | | 2,082 |
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
The Company’s lease obligations are as follows:
| | | | | | | | | | |
| | 2023 | | |
| | $ | | |
Balance – January 1 | | 3,066 | | | |
Additions | | 357 | | | |
| | | | |
Interest accretion | | 59 | | | |
Lease repayments | | (451) | | | |
Effects of foreign exchange | | 26 | | | |
Balance – March 31 | | 3,057 | | | |
| | | | |
Current | | 1,626 | | | |
Non-current | | 1,431 | | | |
| | 3,057 | | | |
Expenses incurred for the three months ended March 31, 2023 and 2022 relating to short-term leases and leases of low-value assets were $38 and $62, respectively.
| | | | | | | | | | | | | | | | | | | | | | | |
| Furniture and office equipment | | Leasehold improvements | | Land and Building | | Total |
| $ | | $ | | $ | | $ |
Cost | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Balance – December 31, 2022 | 2,983 | | | 1,864 | | | 332 | | | 5,179 | |
Additions | 86 | | | 21 | | | — | | | 107 | |
| | | | | | | |
Effects of foreign exchange | 29 | | | 21 | | | 9 | | | 59 | |
Balance – March 31, 2023 | 3,098 | | | 1,906 | | | 341 | | | 5,345 | |
| | | | | | | |
Accumulated depreciation | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Balance – December 31, 2022 | 1,493 | | | 979 | | | 83 | | | 2,555 | |
Depreciation | 202 | | | 81 | | | 3 | | | 286 | |
Effects of foreign exchange | 20 | | | 11 | | | 4 | | | 35 | |
Balance – March 31, 2023 | 1,715 | | | 1,071 | | | 90 | | | 2,876 | |
| | | | | | | |
Carrying value | | | | | | | |
Balance – December 31, 2022 | 1,490 | | | 885 | | | 249 | | | 2,624 | |
Balance – March 31, 2023 | 1,383 | | | 835 | | | 251 | | | 2,469 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Acquired | | |
| | Customer relationships | | Technology | | Trademarks | | Total |
| | $ | | $ | | $ | | $ |
Cost | | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balance – December 31, 2022 | | 1,335 | | | 502 | | | 43 | | | 1,880 | |
| | | | | | | | |
Effects of foreign exchange | | 25 | | | 10 | | | 1 | | | 36 | |
Balance – March 31, 2023 | | 1,360 | | | 512 | | | 44 | | | 1,916 | |
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Acquired | | |
| | Customer relationships | | Technology | | Trademarks | | Total |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
Balance – December 31, 2022 | | 483 | | | 218 | | | 29 | | | 730 | |
Amortization | | 56 | | | 25 | | | 4 | | | 85 | |
Effects of foreign exchange | | 9 | | | 4 | | | 3 | | | 16 | |
Balance – March 31, 2023 | | 548 | | | 247 | | | 36 | | | 831 | |
| | | | | | | | |
Carrying value | | | | | | | | |
Balance – December 31, 2022 | | 852 | | | 284 | | | 14 | | | 1,150 | |
Balance – March 31, 2023 | | 812 | | | 265 | | | 8 | | | 1,085 | |
| | | | | |
| $ |
| |
| |
| |
Balance – December 31, 2022 | 5,982 | |
| |
Effects of foreign exchange | 77 | |
Balance – March 31, 2023 | 6,059 | |
| |
| | | | | |
9 | Finance income and expenses |
Finance income for the three months ended March 31, 2023 and 2022 is comprised of:
| | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
| | | | | | | |
Interest on contingent consideration | | | | | 16 | | | 16 | |
Interest on lease obligations | | | | | 59 | | | 75 | |
| | | | | | | |
Interest income | | | | | (2,242) | | | (110) | |
| | | | | | | |
| | | | | (2,167) | | | (19) | |
| | | | | | | | | | | |
Authorized: | | | |
Unlimited common shares with no par value | | | |
Issued and outstanding: | | | |
| Number of shares | | Amount |
| # | | $ |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Balance – December 31, 2022 | 32,913,955 | | | 268,194 | |
Stock option exercise | 8,735 | | | 149 | |
Share issuance under ESPP | 8,785 | | | 322 | |
| | | |
RSU release | 5,249 | | | 224 | |
| | | |
| | | |
| | | |
Balance – March 31, 2023 | 32,936,724 | | | 268,889 | |
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
| | | | | |
11 | Share-based compensation |
| | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Stock options | | | | | 566 | | | 397 | |
DSUs | | | | | 229 | | | 204 | |
RSUs | | | | | 437 | | | 449 | |
ESPP | | | | | 35 | | | 44 | |
| | | | | 1,267 | | | 1,094 | |
There were no PSUs issued and outstanding for the three months ended March 31, 2023 and 2022.
The following table presents share-based compensation expense by function for the three months ended March 31:
| | | | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Cost of revenue | | | | | 25 | | | 107 | |
General and administrative | | | | | 733 | | | 675 | |
Sales and marketing | | | | | 445 | | | 346 | |
Research and development | | | | | 64 | | | (34) | |
| | | | | 1,267 | | | 1,094 | |
The changes in the number of stock options during the three months ended March 31, 2023 and 2022 were as follows:
| | | | | | | | | | | | | | | | | | | | | | | |
| 2023 | | 2022 |
| Number of options | | Weighted average exercise price | | Number of options | | Weighted average exercise price |
| # | | C$ | | # | | C$ |
Options outstanding – January 1 | 1,349,001 | | | 13.60 | | | 1,283,088 | | | 12.00 | |
Options granted | 207,127 | | | 52.38 | | | 34,667 | | | 54.26 | |
Options forfeited | (11,915) | | | 46.32 | | | (1,897) | | | 16.00 | |
Options exercised | (8,735) | | | 16.00 | | | (34,853) | | | 34.62 | |
| | | | | | | |
Options outstanding – March 31 | 1,535,478 | | | 18.56 | | | 1,281,005 | | | 12.52 | |
Options exercisable – March 31 | 1,003,393 | | | 4.83 | | | 891,286 | | | 3.84 | |
The weighted average fair value of share options granted during the three months ended March 31, 2023 and 2022 was estimated at the date of grant using the Black-Scholes option pricing model using the following inputs:
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
| | | | | | | | | | | |
| |
| 2023 | | 2022 |
| C$ | | C$ |
Weighted average stock price valuation | $ | 52.38 | | | $ | 54.26 | |
Weighted average exercise price | $ | 52.38 | | | $ | 54.26 | |
Risk-free interest rate | 2.98 | % | | 2.03 | % |
Expected life in years | 4.5 | | 6.25 |
Expected dividend yield | — | % | | — | % |
Volatility | 65 | % | | 61 | % |
Weighted average fair value of options issued | $ | 28.26 | | | $ | 31.67 | |
The following table is a summary of the Company’s stock options outstanding as at March 31, 2023:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Options outstanding | | Options exercisable |
Exercise price range | | Number outstanding | | Weighted average remaining contractual life (years) | | Exercise price range | | Number exercisable |
C$ | | # | | # | | C$ | | # |
0.0001 - 1.09 | | 784,368 | | | 4.21 | | 0.0001 - 1.09 | | 784,368 | |
| | | | | | | | |
8.86 - 11.06 | | 51,811 | | | 7.71 | | 8.86 - 11.06 | | 35,126 | |
15.79 - 16.00 | | 246,312 | | | 6.53 | | 15.79 - 16.00 | | 139,060 | |
26.43 - 95.12 | | 452,987 | | | 7.57 | | 26.43 - 95.12 | | 44,839 | |
| | 1,535,478 | | | 5.57 | | | | 1,003,393 | |
The following table is a summary of the Company’s stock options outstanding as at March 31, 2022:
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Options outstanding | | Options exercisable |
Exercise price range | | Number outstanding | | Weighted average remaining contractual life (years) | | Exercise price range | | Number exercisable |
C$ | | # | | # | | C$ | | # |
0.0001 - 1.09 | | 784,368 | | | 5.21 | | 0.0001 - 1.09 | | 748,368 | |
| | | | | | | | |
8.86 - 11.06 | | 54,553 | | | 8.47 | | 8.86 - 11.06 | | 23,826 | |
15.79 - 16.00 | | 275,697 | | | 7.53 | | 15.79 - 16.00 | | 100,509 | |
26.43 - 95.12 | | 166,387 | | | 9.33 | | 26.43 - 95.12 | | 18,583 | |
| | 1,281,005 | | | 6.39 | | | | 891,286 | |
DSUs
The following table presents information concerning the number of DSUs granted by the Company:
| | | | | |
| # |
| |
| |
| |
| |
| |
DSUs – December 31, 2022 | 87,222 | |
Granted (at C$43.93 per unit) | 1,862 | |
| |
| |
DSUs - March 31, 2023 | 89,084 | |
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
RSUs
The following table presents information concerning the number of RSUs granted by the Company:
| | | | | |
| # |
| |
| |
RSUs – December 31, 2022 | 103,626 | |
Granted (at C$52.38 per unit) | 111,724 | |
Released (at C$54.26 - $86.38 per unit) | (5,249) | |
Forfeited (at C$54.26 - $86.38 per unit) | (3,509) | |
RSUs - March 31, 2023 | 206,592 | |
| | | | | |
12 | Income (loss) per share |
Basic and diluted net income (loss) per share for the three months ended March 31 are calculated as follows:
| | | | | | | | | | | | | | | |
| | | |
| | | | | 2023 | | 2022 |
Net income (loss) attributable to common shareholders | | | | | $ | 1,245 | | | $ | (6,959) | |
| | | | | | | |
Basic weighted average number of common shares outstanding | | | | | 33,153,231 | | | 33,017,421 | |
Stock options | | | | | 802,418 | | | — | |
DSUs | | | | | 89,043 | | | — | |
RSUs | | | | | 114,959 | | | — | |
Diluted weighted average number of common shares outstanding1 | | | | | 34,159,651 | | | 33,017,421 | |
| | | | | | | |
Basic net income (loss) per common share | | | | | $ | 0.04 | | | $ | (0.21) | |
Diluted net income (loss) per common share1 | | | | | $ | 0.04 | | | $ | (0.21) | |
1Diluted weighted average number of common shares outstanding for the three months ended March 31, 2023 excludes 23,782 stock options (2022 – 1,027,646 stock options, 60,380 DSUs, and 48,341 RSUs) as their effects are anti-dilutive.
| | | | | |
13 | Revenue and related balances |
Disaggregated revenue
The Company derives its revenues from two main sources, subscription to its SaaS application, and professional services revenue, which includes services such as initial implementation, project management, and training.
The following table presents a disaggregation of revenue for the three months ended March 31:
| | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Subscription revenue | | | | | 38,844 | | | 29,128 | |
Professional services | | | | | 2,615 | | | 2,927 | |
| | | | | 41,459 | | | 32,055 | |
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
The following table represents cost of revenue for the three months ended March 31:
| | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Employee salaries and benefits | | | | | 4,586 | | | 4,159 | |
Web hosting fees | | | | | 1,177 | | | 1,057 | |
Third party service fees | | | | | 2,123 | | | 1,173 | |
Other | | | | | 168 | | | 163 | |
| | | | | 8,054 | | | 6,552 | |
The total employee compensation comprising salaries and benefits, inclusive of tax credits, and excluding share-based compensation for the three months ended March 31, 2023 was $26,068 (2022 - $21,875).
Employee compensation costs were included in the following expenses for the three months ended March 31:
| | | | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Cost of revenue | | | | | 4,586 | | | 4,159 | |
General and administrative | | | | | 3,510 | | | 3,365 | |
Sales and marketing | | | | | 11,967 | | | 9,707 | |
Research and development | | | | | 6,005 | | | 4,644 | |
| | | | | 26,068 | | | 21,875 | |
| | | | | |
16 | Related party transactions |
Key management personnel are those persons having the authority and responsibility for planning, directing and controlling activities of the Company, directly or indirectly, including the Chief Executive Officer, President and Chief Operating Officer, Chief Financial Officer, Chief Product Officer, Chief Corporate Development Officer, Chief Human Resource Officer, Chief Legal Officer and Directors.
Compensation expense for the Company’s key management personnel for the three months ended March 31, 2023 and 2022 is as follows:
| | | | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
Salaries and benefits | | | | | 946 | | | 807 | |
Share-based compensation | | | | | 1,106 | | | 668 | |
| | | | | 2,052 | | | 1,475 | |
| | | | | |
17 | Financial instruments and risk management |
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from deposits with banks and outstanding receivables. The
DOCEBO INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2023
(expressed in thousands of US dollars, except share amounts)
Company trades only with recognized, creditworthy third parties. Due to the Company’s diversified customer base, there is no particular concentration of credit risk related to the Company’s trade and other receivables. Trade and other receivables are monitored on an ongoing basis to ensure timely collection of amounts.
The carrying values of cash and cash equivalents, trade and other receivables, and trade and other payables approximate fair values due to the short-term nature of these items or being carried at fair value. The risk of material change in fair value is not considered to be significant. The Company does not use derivative financial instruments to manage this risk.
Contingent consideration is classified as a Level 3 financial instrument. The fair value of the contingent consideration was calculated using discounted cash flows. During the three months ended March 31, 2023, there were no transfers of amounts between levels in the fair value hierarchy.
The Company reports segment information based on internal reports used by the chief operating decision maker (“CODM”) to make operating and resource allocation decisions and to assess performance. The CODM is the Chief Executive Officer. The CODM makes decisions and assesses performance of the Company on a consolidated basis such that the Company is a single reportable operating segment.
The following tables present details on revenues derived in the following geographical locations for the three months ended March 31, 2023 and 2022.
| | | | | | | | | | | | | | | |
| | | Three months ended March 31, |
| | | | | 2023 | | 2022 |
| | | | | $ | | $ |
North America | | | | | 31,477 | | | 23,855 | |
Rest of World | | | | | 9,982 | | | 8,200 | |
| | | | | 41,459 | | | 32,055 | |
In April 2023, the Company acquired all of the issued and outstanding shares of Circles Collective Inc. (o/a PeerBoard), a plug and play community-as-a-service platform. The acquisition of PeerBoard will expand Docebo’s external training offering and enhance the Company’s social learning capabilities. The acquisition will be accounted for as a business combination in accordance with IFRS 3, Business Combinations.
Total purchase consideration was $4,026, consisting of: (i) cash paid on closing of $2,526; (ii) issuance of 26,185 common shares of Docebo Inc. with total fair value of $1,000; and (iii) $500 of cash payable of which 50% is due on the first year anniversary and the remaining 50% is due on the second year anniversary of the acquisition, subject to any representations and warranties deductions. In addition, potential future consideration of up to $4,000 in cash over the three years following the closing date is owing to an employee of the acquiree based on the achievement of both performance milestones and continued employment. Given the continued employment requirement, these earn-out payouts will be accounted for as compensation for post-acquisition services and are not considered purchase consideration in the business combination.
The assessment of the purchase price and the accounting for this acquisition has not yet been finalized and certain IFRS 3 disclosures have not been included due to the timing of the acquisition.